Editorial: The burden of stress and depression – new insight into faster and efficient treatment

[...]there is currently no reliable biomarker for the early detection of mood disorders. [...]pretreatment with the GLT1 inhibitor DHK significantly alleviated the rapid antidepressant-like effect of ketamine infusion. While Ketamine is a promising candidate for treating depression and anxiety, it has some acute side effects, and more importantly, its chronic use is associated with potentially severe and possibly persistent toxic effects (Short et al., 2018). [...]the search for a safe and side-effect-free treatment is still ongoing. Ten-day treatment alleviated anxiety and depression like-behaviors, attenuated plasma corticosterone concentrations, decreased pro-inflammatory cytokines mRNA levels, and increased hippocampal phosphorylated cAMP response element-binding protein (pCREB) and brain-derived neurotrophic factor (BDNF).